Ernexa Therapeutics Inc. Interest Expense on Debt
Ernexa Therapeutics Inc. (ERNA) reported Interest Expense on Debt of $22.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2026-08-06
- Ernexa Therapeutics Inc. interest expense, debt for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. interest expense, debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. interest expense, debt for the quarter ending 2025-06-30 was $16.00K, a 6.67% increase year-over-year.
- Ernexa Therapeutics Inc. interest expense, debt for the quarter ending 2025-03-31 was $6.00K, a 98.53% decline year-over-year.
- Ernexa Therapeutics Inc. interest expense, debt for fiscal 2025 was $22.00K, a 87.36% decline from fiscal 2024.
- Ernexa Therapeutics Inc. interest expense, debt for fiscal 2024 was $174.00K, a 1.14% decline from fiscal 2023.
- Ernexa Therapeutics Inc. interest expense, debt for fiscal 2023 was $176.00K.
- Ernexa Therapeutics Inc. interest expense, debt for fiscal 2022 was $0.00.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $16.00K derived: sum of 3 quarters · filed 2026-08-06 | $22.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $16.00K derived: sum of 2 quarters · filed 2026-08-06 | $22.00K 10-Q · filed 2025-11-07 | -$245.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.00K 10-Q · filed 2026-08-06 | -$245.00K derived: sum of 3 quarters · filed 2026-08-06 | -$226.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.00K 10-Q · filed 2026-05-11 | -$261.00K derived: sum of 2 quarters · filed 2026-05-11 | -$242.00K derived: sum of 3 quarters · filed 2026-05-11 | -$227.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$248.00K derived: sum of 2 quarters · filed 2026-03-13 | -$233.00K derived: sum of 3 quarters · filed 2026-03-13 | $174.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $34.00K derived: sum of 2 quarters · filed 2025-11-07 | $441.00K 10-Q · filed 2025-11-07 | $504.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $422.00K 10-Q · filed 2025-08-13 | $485.00K derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $407.00K 10-Q · filed 2025-05-07 | $470.00K derived: sum of 2 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $176.00K 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $113.00K 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $118.00K 10-K · filed 2021-03-11 | |||
| 2019-12-31 | $236.00K 10-K · filed 2021-03-11 | |||
| 2018-12-31 | $296.00K 10-K · filed 2020-03-19 | |||
| 2017-12-31 | $425.00K 10-K · filed 2019-03-22 | |||
| 2016-12-31 | $517.00K 10-K · filed 2018-03-09 | |||
| 2015-12-31 | $283.00K 10-K · filed 2017-03-09 | |||
| 2014-12-31 | $210.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |